Interactions Between the Intestinal Microbiome and Liver Diseases

Bernd Schnabl* and David A. Brenner
Department of Medicine, University of California San Diego, La Jolla, CA

Abstract

The human intestine harbors a diverse community of microbes that promote metabolism and digestion in their symbiotic relationship with the host. Disturbance of its homeostasis can result in disease. We review factors that disrupt intestinal homeostasis and contribute to non-alcoholic fatty liver disease (NAFLD), steatohepatitis (NASH), alcoholic liver disease, and cirrhosis. Liver disease has long been associated with qualitative and quantitative (overgrowth) dysbiotic changes in the intestinal microbiota. Extrinsic factors, such as the Western diet and alcohol, contribute to these changes. Dysbiosis results in intestinal inflammation, a breakdown of the intestinal barrier, and translocation of microbial products in animal models. However, the contribution of the intestinal microbiome to liver disease goes beyond simple translocation of bacterial products that promote hepatic injury and inflammation. Microbial metabolites produced in a dysbiotic intestinal environment and host factors are equally important in the pathogenesis of liver disease. We review how the combination of liver insult and disruptions in intestinal homeostasis contribute to liver disease.

Keywords

Microbiota; endotoxin; alcoholic steatohepatitis

Introduction

The intestine and its microbiota (bacteria and other microbes) have a symbiotic relationship. The microbiota contributes to digestion, synthesis of vitamins, and resistance to intestinal colonization by pathogens, but also contains potentially pathogenic bacteria. Disruption of intestinal homeostasis and alterations in the intestinal microbiome contribute to the pathogenesis of many disorders, including liver disease. How do disturbances in the intestinal microbiome (detected by analyses of its metagenome and metabolome) contribute
to liver disease? We discuss how host and dietary factors, including alcohol, affect the composition of the intestinal microbiome and development of liver diseases, and in turn, how liver disease can alter the enteric microbiome. We review alterations in the composition of the intestinal microbiome associated with several liver diseases. These studies were performed primarily in patients with disease (see Tables 1 and 2). The functional consequences of the intestinal microbiome for each of these diseases, based primarily on animal models, are then reviewed in the following section.

### Intestinal Microbiome Composition and Liver Disease

#### Non-alcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH)

NAFLD is the hepatic manifestation of the metabolic syndrome. NAFLD is generally a benign disease; approximately one third of the US population has hepatic steatosis. The prevalence of NASH among a general medical population diagnosed with NAFLD is 30%. NASH is characterized by the development of liver inflammation and fibrosis. Patients with NASH have a high likelihood of developing advanced fibrosis and cirrhosis; it has been estimated that about one third of cases of early-stage NASH will progress to stage 3 or 4 fibrosis (cirrhosis) over 5–10 years.

Dietary factors and changes in diet are determinants of the composition of the microbiome. Although patients with NAFLD are often obese and insulin resistant, we focus on published studies of patients with documented liver disease, rather than obesity. The fecal microbiota in NAFLD and NASH patients has been assessed using culture-independent techniques such as quantitative PCR and deep sequencing of a conserved region in the bacterial 16S rRNA gene. Details about dysbiosis associated with NAFLD and NASH are summarized in Table 1. Microbiota samples from patients with NAFLD or NASH have a lower proportion of members of the family Ruminococcaceae than healthy subjects. *Escherichia* is the only abundant genus of bacteria in the intestinal microbiota that is significantly disproportionate between obese children and pediatric patients with NASH. In contrast, adult patients with NASH had a significantly higher percentage of *Clostridium coccoides* than patients with biopsy-proven NAFLD. However, studies comparing the bacterial taxonomic composition of patients with NAFLD vs those with NASH produced variable and even contradictory findings. Possible reasons for discrepant results include small number of subjects included in the studies, differences in cohorts (age, sex, ethnicity, geographical location, medication use), insufficient documentation of liver disease, and differences in methodology. To determine whether patients with NAFLD and NASH have distinct compositions of the intestinal microbiome, studies (ideally longitudinal) are needed of larger, better characterized cohorts. Identifying specific microbial compositions of these patients could improve our understanding of intestine–liver interactions and lead to fecal biomarkers for NAFLD and/or NASH.

Small bowel bacterial overgrowth is a disorder in which abnormally large numbers of bacteria grow in the small intestine. Patients with obesity or NAFLD have a higher prevalence small intestinal bacterial overgrowth. Intestinal permeability and bacterial overgrowth correlate with severity of steatosis, but not fibrosis or hepatic inflammation, based on liver biopsy analysis. Small intestinal bacterial overgrowth was also present in
50% of patients with NASH, which is significantly higher than in healthy controls, matched for sex and age. In these studies, patients with small intestinal bacterial overgrowth were identified by breath tests. However, researchers have debated whether breath tests accurately detect this disorder. Total bacterial counts in the feces, based on real-time PCR, did not differ between healthy subjects and persons with NAFLD or NASH. Further studies are needed to determine whether fecal bacterial counts actually correlate with the amount of microbes present in the small intestine. Culture-and breath test-independent methods are needed to reassess the prevalence of intestinal bacterial overgrowth in patients with NAFLD or NASH.

**Alcoholic Liver Disease**

Alcohol abuse is one of the leading causes of chronic liver disease. Chronic alcoholic liver disease may progress from simple steatosis to steatohepatitis, liver fibrosis, and in 15%–40% of patients, cirrhosis. Patients with only alcoholic fatty liver disease usually do not present with any clinical symptoms and their liver continues to function well.

Research into the role of the microbiome in alcoholic liver disease is unfortunately not as advanced as that for obesity or fatty liver disease. The mucosa-associated bacterial taxonomy was evaluated in patients with alcoholic cirrhosis and alcoholics without liver disease using 16S rRNA gene sequencing. The proportion of Bacteroidaceae was lower in samples from alcoholic patients than from non-alcoholic individuals.

Although microbiome studies in humans are important to associate distinct compositions of the intestinal microbiome with different disease states, studies in animal models, under carefully controlled conditions, offer some advantages. Preclinical studies allow researchers to control for age, sex, environment, diet, and genetic background. Littermates can be compared in mouse studies. Pups are typically colonized with the microbes they first encounter, typically from their mothers, so littermates usually have the same microbiota composition. Changes in the microbiota can be monitored in response to different environmental factors, and compared among mice that had the same initial microbial composition.

For example, in the Tsukamoto-French model of alcoholic liver disease, mice are placed on specific liquid diets and given intragastric infusions of ethanol, whereas control littermates are placed on the same diet but instead given an isocaloric amount of dextrose. Using this system, researchers have been able to detect quantitative and qualitative changes in the microbiome associated with ethanol intake. Bacterial overgrowth was observed along almost the entire gastrointestinal tract; the dysbiosis was characterized by significant reductions in proportions of probiotic bacteria such as *Lactobacillus, Pediococcus, Leuconostoc* and *Lactococcus*. An alcohol-associated decrease in the number of intestinal *Lactobacillus*, confirmed by quantitative real-time PCR, was also observed in the Lieber DeCarli diet model of alcohol feeding for 8 weeks (unpublished data). Alternatively, several studies have reported that administration of probiotic *Lactobacillus* reduces features of alcoholic liver disease in animal models. A small clinical trial has also demonstrated improve alcohol-induced liver injury in patients taking probiotics. Similar to observations made in animal models, aerobic and anaerobic bacterial cultures of jejunal aspirates from patients who
chronically abuse alcohol were found to have bacterial overgrowth. Excessive alcohol intake is therefore accompanied by dysbiosis and an increased intestinal bacterial load, based on clinical and preclinical studies.

Multiple factors are likely to contribute to changes in the intestinal microbiome during development of alcoholic liver disease. These might include small intestinal dysmotility, changes in gastric acid secretion, and alterations to the intestinal innate immune response. Antimicrobial molecules, which are part of the innate immune response, are secreted from enterocytes or intestinal Paneth cells. In particular, the antimicrobial molecules regenerating islet-derived (Reg)3b and Reg3g are reduced in the small intestines of mice following 3 weeks of intragastric ethanol feeding. Further studies are needed to determine if and to what extent an impaired innate immune response contributes to disease progression. The commensal microbiota not only produces ethanol, but also metabolizes it. It is not clear whether ethanol, as a dietary component or as an energy source for certain bacterial strains, directly alters the microbiota.

Cirrhosis

Liver fibrosis may result in end-stage liver disease or cirrhosis, which eventually disrupts the metabolic functions of the liver. Although patients with hepatic fibrosis are often asymptomatic, development of cirrhosis in these patients is the major determinant of morbidity and mortality. Major clinical complications are infections, ascites, renal failure, variceal hemorrhage, and hepatic encephalopathy. Patients with these complications have a poor prognosis and liver transplantation is often indicated.

Several studies assessed the taxonomic composition of the intestinal microbiota in patients with cirrhosis (see Table 2). A common feature of cirrhosis is an increase of potentially pathogenic bacteria, accompanied by reduced proportions of beneficial bacteria. Fecal microbial communities are similar among patients with cirrhosis of different etiologies. Therefore, features of end-stage liver disease, such as reduced bile flow, might determine the shape of the intestinal microbiome. However, fecal microbial communities from patients with alcoholic cirrhosis have significant increases in the family of Prevotellaceae compared to patients with hepatitis B-related cirrhosis or healthy individuals, based on sequencing of the common 16S rRNA gene region of bacteria. Etiology (particularly an alcohol association) therefore appears to contribute to the composition of the intestinal microbiome in patients with end-stage liver disease.

Most patients with cirrhosis have intestinal bacterial overgrowth, demonstrated by quantitative analyses of bacterial cultures from jejunal aspirates. So, they not only have taxonomic differences in microbial communities, compared to people without cirrhosis, but also an increased intestinal burden of bacteria. Several factors contribute to intestinal bacterial overgrowth in patients with cirrhosis. These include impaired motility of the small intestine, reduced bile flow, and altered secretion of immunoglobulin A and antimicrobial molecules. In rats with cirrhosis, ascites, and translocation of viable bacteria to mesenteric lymph nodes, Paneth cells produce lower levels of defensins and Reg3 molecules, compared to those without bacterial translocation. This reduction is accompanied by reduced antimicrobial activity against Enterobacteriaceae. Little is known about how...
Paneth cell function is impaired during development of cirrhosis. Compromised intestinal host defense might therefore contribute to qualitative and quantitative changes in the enteric microbiome associated with end-stage liver disease. New sequencing techniques to analyze the microbiome should help determine the contribution of these factors to compositional changes in the microbiota.

**Functional Consequences of Changes in the Intestinal Microbiome**

**NAFLD and NASH**

Most patients with NAFLD are obese and diabetic. Obesity and insulin resistance are risk factors for fatty liver disease and are associated with changes in the intestinal microbiome\(^{37,38}\). The intestinal microbiome is an important factor in the development of obesity; germ-free mice are protected from high fat diet-induced weight gain and obesity\(^{39,40}\).

Changes in bacterial taxonomy might not be as important as changes in bacterial genes (metagenomics and metatranscriptomics) in the development of NAFLD and NASH\(^{41}\). Obesity is accompanied by an intestinal metagenome that has an increased capacity to collect energy from the host diet. Bacterial enzymes aid in digestion of otherwise indigestible dietary polysaccharides and extraction of calories from them\(^{37}\). In addition, enteric bacteria suppress the synthesis of fasting-induced adipocyte factor (Fiaf; also known as angiopoietin-like 4) and secretion from the small intestine, resulting in increased activity of lipoprotein lipase (LPL) and increased accumulation of triglycerides in the liver\(^{39,40}\). This process provides a direct link between the intestinal microbiome and fat deposition in the liver.

Complex interactions between the enteric microbiome and the host are often mediated by metabolites. Several changes in bacterial metabolites have been associated with obesity, and in particular, with NAFLD. One of these metabolites is ethanol, a product of the intestinal microbiome. Obese animals have higher blood concentrations of ethanol, determined by breath tests, than lean animals\(^{42}\). Alcohol is absorbed and reaches the liver via the portal blood. Ethanol causes triglyceride accumulation in hepatocytes\(^{43}\), and might also provide a second hit to livers that have already accumulated fat, via production of reactive oxygen species and initiation of liver inflammation. Obese children with NAFLD do not have increased blood levels of ethanol, whereas pediatric patients with NASH do\(^{7}\). Metatranscriptomic and metabolomic studies of intestinal contents are needed for further analysis and confirmation.

Choline is another important metabolite that has been implicated in the pathogenesis of NAFLD and NASH. Choline deficiency in the diet has been linked to liver disease for a long time\(^{44}\). Choline-deficient diets are used to create rodent models of NASH. However, until recently, it was not known that choline deficiency could occur under pathophysiologic conditions. High-fat diets lead to formation of intestinal microbiota that convert dietary choline into methylamines, reducing circulating plasma levels of phosphatidylcholine to produce similar effects of choline-deficient diets and causing NASH\(^{45}\). Phosphatidylcholine is necessary for the assembly and secretion of very-low-density lipoprotein (VLDL)\(^{46}\).
Microbiota-induced choline deficiency therefore results in triglyceride accumulation in hepatocytes, secondary to lower hepatic secretion of VLDL, whereas the increase of plasma level of trimethylamine (TMA) and its hepatic metabolism to trimethylamine-N-oxide (TMAO) have been linked to atherosclerosis and cardiovascular disease. People with choline-deficient diets develop fatty liver, based on MRI imaging studies. However, a single-nucleotide polymorphism in the promoter region of PEMT (rs12325817), which affects de novo synthesis of phosphatidylcholine, is required for development of a fatty liver. Taken together, diet-induced changes in the intestinal microbiome can produce dramatic changes in metabolites in the host.

Microbial products contribute to the pathogenesis of NAFLD and NASH. Children with NAFLD had markedly higher serum concentrations of endotoxin than control subjects. Endotoxemia was also observed in patients with NASH. The most convincing evidence for the importance of translocated microbial products comes from preclinical studies of NAFLD. Signaling via toll-like receptor (TLR)4, a receptor for lipopolysaccharide (LPS), in hematopoietic-derived cells is required for the development of liver steatosis, but not for the development of obesity in mice. Mice deficient in sensing pathogen-associated molecular patterns (PAMPs) or downstream signaling are resistant to NASH. Microbial products reach the liver via the portal circulation and cause inflammation, among other effects. Genetically obese mice are more sensitive to endotoxin-induced hepatotoxicity and develop steatohepatitis after exposure to low doses of LPS. Increased intestinal permeability and disruption of the mucosal barrier are required for microbial products to translocate from the intestinal lumen to extra-intestinal space. Patients with NAFLD have significantly increased intestinal permeability and alterations in the intestinal tight junctions, compared to healthy individuals. Bacterial overgrowth is particularly important in patients with a leaky gut because it increases the luminal amount of PAMPs.

But what causes the onset of intestinal barrier dysfunction? Intestinal inflammation might cause intestinal leakage and translocation of microbial products. Obesity is accompanied by inflammation in the colorectal mucosa; in obese individuals, diet-induced weight loss reduces colorectal inflammation and alters expression of inflammatory and cancer-related genes. In mice, high-fat diets increase activity of the transcription factor NFκB and expression of tumor necrosis factor (TNF)α in the small intestine. Intestinal inflammation depends on the enteric microbiota; germ-free mice are protected from inflammation of the small intestine. More direct evidence for dysbiosis-induced intestinal inflammation and bacterial translocation has come from studies of mice deficient for Nlrp3 and Nlrp6. These mice cannot form cytoplasmic multi-protein complexes composed of nucleotide-binding domain and leucine-rich repeat containing proteins (NLRPs), called inflammasomes. Inflammasomes are sensors of exogenous PAMPs or endogenous damage-associated molecular patterns (DAMPs) that regulate cleavage of precursors to inflammatory cytokines such as pro-interleukin (IL)1β and pro-IL18. In mice, loss of Nlrp3 and Nlrp6 inflammasomes is associated with intestinal dysbiosis and eventual inflammation of the colon, via the chemokine CCL5. Dysbiosis is characterized by an increase in Prevotella. Subsequent microbe translocation leads to increased accumulation of bacterial products such as LPS and bacterial DNA in the portal vein. These bacterial products induce an
inflammatory response in the liver that promotes progression of NAFLD to NASH. Importantly, this phenotype can be transmitted, by co-housing wild type and NASH-prone mice. Dysbiosis therefore induces colonic inflammation and bacterial translocation, causing simple hepatic steatosis to turn into NASH. Dysbiosis is therefore a significant contributor to liver disease. This study also demonstrated how features of the host can determine the composition of the microbiome.

In summary, diet- and host-induced changes in the intestinal microbiota contribute to the onset of NAFLD and NASH (Figure 1). Changes in the intestinal microbiota can affect the liver via translocated microbial products or absorbed bacterial metabolites. Alternatively, direct host–microbiota interactions in the intestine alter intestinal homeostasis, affecting the liver as distant organ.

**Alcoholic Liver Disease**

A prominent feature of alcohol abuse is disruption of the intestinal barrier. Animal models of alcoholic liver disease have leaky gut, and patients have impairments to the intestinal barrier. There is debate over which marker is reliable for identification of patients with leaky intestine. Arguably the best method to assess increased intestinal permeability is direct measurement of bacterial products that originate only from the intestinal lumen, and must therefore have translocated into the extra-intestinal space, blood, and organs. Alcoholics with no evidence of liver disease and patients with alcoholic hepatitis or alcohol-associated cirrhosis have higher plasma levels of endotoxin than healthy controls.

Does the intestinal microbiome initiate and mediate an increase in intestinal permeability? Intestinal sterilization protects against alcohol-induced intestinal barrier leakage and prevents bacterial translocation. Although mice that express nonfunctional Tlr4 are protected from experimental alcoholic liver disease, levels of endotoxin in the portal vein increase to levels similar to those of mice that express wild-type Tlr4, indicating that Tlr4 does not control intestinal permeability.

So how might the intestinal microbiota increase intestinal permeability? Intestinal bacteria metabolize ethanol and produce acetaldehyde. Ethanol and its metabolic derivative, acetaldehyde, disrupt tight junction integrity. The intestinal microbiome also synthesizes ethanol, which might have deleterious effects on the intestinal barrier. Alternatively, a decrease in commensal probiotics could contribute to loss of the protective tight junction barrier. A mast cell membrane stabilizer prevents ethanol-induced epithelial barrier alteration in vivo. Intestinal inflammatory cells such as mast cells might therefore contribute to the onset of a leaky intestine, and could be activated by qualitative and/or quantitative changes in the microbiome. Further metagenomic and metabolomic studies are needed to determine the functional contribution of the intestinal microbiome to barrier dysfunction and thereby alcoholic liver disease. Alcohol-induced liver disease itself could decrease the intestinal barrier, by increasing systemic levels of IL1β or TNFα, which disrupt tight junctions. It is not clear to what extent changes in liver function contribute to mucosal barrier defects.
Intestinal bacterial overgrowth and dysbiosis are important factors in the pathogenesis of alcoholic liver disease in patients with leaky intestine. Increased intestinal permeability facilitates translocation of microbial products from the intestinal lumen to extraintestinal organs. Mice that are protected from bacterial overgrowth have decreased alcohol-induced liver disease despite leakier guts\textsuperscript{16}. Similarly, rats fed non-absorbable antibiotics that reduce the load of Gram-negative bacteria in the intestine have lower systemic levels of endotoxin and develop less-severe liver disease following ethanol administration\textsuperscript{60}. Ethanol-induced liver inflammation and injury were also significantly lower in mice that express nonfunctional Tlr4 compared with mice that express the wild-type protein\textsuperscript{62}, providing further evidence for the role of bacterial products in alcoholic liver disease.

Microbial products translocate from the intestine to the liver in humans and animal models after ethanol intake. In patients or animals with leaky intestine, the total intraluminal load of enteric bacteria determines the amount of translocated bacterial products. PAMPs reach the liver via the portal system. Alcohol, as an initiating liver insult, and microbial products might synergize to promote progression of liver disease. Changes in the intestinal microbiome (particularly bacterial overgrowth) and increased bacterial translocation contribute to alcoholic liver disease (see Figure 2).

**End-stage Liver Disease**

The intestinal microbiome has been implicated in complications of cirrhosis such as hepatic encephalopathy and infections. Increased levels of endotoxin, systemic inflammation, and production of ammonia (a bacterial byproduct) contribute to pathogenesis of hepatic encephalopathy\textsuperscript{67}. Intestinal decontamination with non-absorbable antibiotics such as rifaximin is effective treatment for subclinical and overt hepatic encephalopathy\textsuperscript{68, 69}.

Bacterial translocation occurs in healthy individuals and is important for immune system development, but can also be harmful. Translocation of microbial products contributes to progression of NAFLD, NASH, and alcoholic liver disease. In patients with cirrhosis, bacterial translocation induces inflammation and hemodynamic derangement\textsuperscript{70}, and can cause serious infections, with reported 38% mortality\textsuperscript{71}. Infections such as spontaneous bacterial peritonitis and bacteremia develop in patients with end-stage liver disease, caused by migration of intestinal bacteria into the peritoneal cavity or circulation.

Several mechanisms contribute to intestinal translocation of bacteria in patients with cirrhosis, such as a leaky intestinal barriers and immune deficits\textsuperscript{72}. Some of these mechanisms are closely related to the content of the intestinal microbiome. Most infections (approximately 80%) are caused by Gram-negative bacilli–especially *Escherichia coli*\textsuperscript{70}. Interestingly, bacteria from the family Enterobacteriaceae (including *E coli*, *Klebsiella*, *Proteus*, and *Enterobacter*) increase in the microbiota of patients with cirrhosis\textsuperscript{27, 28, 31, 32}. Small intestinal bacterial overgrowth in patients with cirrhosis was associated with systemic endotoxemia and found to predispose animal models of cirrhosis to bacterial translocation\textsuperscript{30, 31, 70}. Overgrowth of a dysbiotic microbiota might make a major contribution to translocation of viable bacteria and thereby infections. A small observational study highlighted the clinical importance of intestinal bacterial overgrowth in patients with decompensated cirrhosis. Intestinal decontamination with the non-absorbable antibiotics
rifaximin reduced endotoxemia and reduced the severity of liver disease\textsuperscript{73}. Randomized placebo-controlled trials are needed to confirm these preliminary findings.

Other factors that contribute to bacterial translocation include intestinal inflammation and changes in intestinal immune surveillance. Patients with liver cirrhosis were found to have inflammation of the duodenum, which could promote leakiness\textsuperscript{74}. Rats with cirrhosis have increased numbers of activated CD103\textsuperscript{+} dendritic cells in the lamina propria and mesenteric lymph nodes, with detectable bacterial DNA but no viable bacteria in the mesenteric lymph nodes. In contrast, in rats with viable bacteria in mesenteric lymph nodes, CD103\textsuperscript{+} dendritic cells did not appear to be activated, indicating tolerance and exhaustion. Intestinal sterilization prevented bacterial translocation, and reduced the activation and function of CD103\textsuperscript{+} dendritic cells, indicating that the intestinal microbiome, rather than the host, seems to mediate the effects of bacterial translocation\textsuperscript{75}.

Although the intestinal microbiota contributes to progression of liver disease in pre-cirrhotic states, the pathologic functions of the intestinal microbiota change during advanced stages of liver disease. Translocated viable bacteria and microbial products make important contributions to clinical complications associated with end-stage liver disease. Bacterial translocation, rather than failed liver function, could be the major determinant of mortality in this patient cohort.

**Interactions Between Liver and Intestine via Bile Acids**

Bile acids mediate communication between the liver and intestine. They are produced as glycine or taurine conjugates in the liver, from cholesterol, for secretion into the small intestine. Conjugated bile acids are absorbed in the terminal ileum to return to the liver. Intestinal bacteria in the large intestine generate secondary bile acids by deconjugation and dehydroxylation. Bile acids are important not only for the absorption of dietary fats and vitamins, they are also ligands for the nuclear receptor farnesoid X receptor (FXR) and the G-protein coupled receptor TGR5. The intestine therefore communicates with the liver via the entero-hepatic circulation.

Not surprisingly, germ-free rats have an altered bile acid profile, characterized predominately by taurine-conjugated bile acids with relatively lower amounts of unconjugated and glycine-conjugated bile acids\textsuperscript{76}. Fecal samples from patients with cirrhosis have reduced total bile acids, likely due to decreased bile flow. Interestingly, the ratio between secondary and primary fecal bile acids is also decreased, possibly from reduced microbial deconjugation\textsuperscript{77}—bacterial gene expression studies are needed to confirm this. Levels of conjugated and unconjugated bile acids are higher in the serum samples from patients with cirrhosis—especially those with advanced-stage disease\textsuperscript{77}. Changes in serum bile acids have also been reported in experimental models of NASH and alcoholic liver disease\textsuperscript{7879}. It is not clear whether the microbiota contributes to these changes.

Bile acids have direct bacteriostatic effects; intestinal bacterial overgrowth might result from the decrease in total fecal bile acids in patients with cirrhosis\textsuperscript{77}. Administration of conjugated bile acids to rats with cirrhosis normalized bile secretion and reduced intestinal bacterial overgrowth and translocation\textsuperscript{80}. Conjugated bile acids bind to FXR in intestinal
epithelial cells, which increases production of the antimicrobial proteins angiogenin 1 and RNase family member 4. These prevent bacterial overgrowth and promote epithelial cell integrity. Bile acids therefore inhibit bacterial proliferation directly and indirectly, by modulating host cells expression of antimicrobial genes.

Microbial modification of bile acids is an important mechanism by which the microbiota can interact with the host and affect not only liver disease, but other organs and metabolic pathways. FXR and TGR5 have been implicated in the metabolic syndrome. Fxr-deficient mice are protected from genetic and diet-induced obesity, but not hepatic steatosis. The FXR agonist obeticholic acid reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and NAFLD in a phase 2 clinical trial. Interestingly, cholestatic liver fibrosis following bile duct ligation is lower in Fxr-deficient mice, but the absence of Fxr had no effect on toxin-induced liver fibrosis. Activation of Tgr5 by bile acids in brown adipose tissue and muscle increased energy expenditure and attenuated diet-induced obesity in mice. The Tgr5 agonist INT-777 caused release of intestinal glucagon-like peptide-1, and reduced adiposity and hepatic steatosis in mice placed on high-fat diets.

Therefore, the intestinal microbiota might contribute to liver disease by modifying intestinal bile acids and regulating FXR and TGR5 signaling. Future studies should investigate how changes in expression of bacterial genes and the bile acid profile affect the host via modulation of FXR and TGR5 and contribute to liver disease.

**Future Directions**

The intestinal microbiome contributes to the onset and progression of alcoholic liver disease and NAFLD, and mediates complications in end-stage liver disease. There appears to be an association between intestinal dysbiosis and liver disease in patients. Changes in the intestinal microbiome were found to cause liver disease mostly in animal models, and few have been associated with metabolic and immunologic features of patients with NAFLD and NASH. Future studies should assess microbial gene expression, proteins, and metabolites, and focus on patients in particular. Increasing our understanding of the delicate homeostasis between the intestine and its microbes could lead to new insights into the pathogenesis of liver disease and therapeutic strategies. There is sufficient evidence to justify a rationale attempt to modulate the intestinal microbiome to treat liver disease. The ultimate goal is to restore eubiosis, which might restore intestinal homeostasis.

**Acknowledgments**

The study was supported in part by NIH grants K08 DK081830, R01 AA020703 to BS, U01 AA021856 to BS and DAB, and 2 P42 ES010337 to DAB.

**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAMP</td>
<td>damage-associated molecular pattern</td>
</tr>
<tr>
<td>Fiaf</td>
<td>fasting induced adipocyte factor</td>
</tr>
</tbody>
</table>
FXR  farnesoid X receptor
IL  interleukin
LPL  lipoprotein lipase
LPS  lipopolysaccharide
NAFLD  non-alcoholic fatty liver disease
NASH  non-alcoholic steatohepatitis
NLRP  NLR family, pyrin domain containing
PAMP  pathogen-associated molecular pattern
Reg3  regenerating islet-derived 3
TLR  Toll-like receptor
TNF  tumor necrosis factor

References


10. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis...


Figure 1. Effects of the Intestinal Microbiota on NAFLD and Progression to Steatohepatitis

High-fat diets (HFD) result in dysbiosis and intestinal bacterial overgrowth. Alterations in the intestinal microbiota increase energy extraction and fermentation of dietary fibers into oligosaccharides, monosaccharides, and short chain fatty acids (SCFA), respectively. Dietary choline is metabolized by the intestinal microbiota to TMA, resulting in choline deficiency. Hepatic choline deficiency results in decreased VLDL efflux, producing hepatic steatosis. Changes in the microbiota also produce ethanol (EtOH), which is absorbed and metabolized in the liver. The intestinal microbiota suppresses gene expression of Fiaf in intestinal epithelial cells, resulting in enhanced activity of LPL and increased levels of free fatty acids (FFA). NLRPs regulate microbial composition via changes of the effector protein IL18. Dysbiosis, in turn, causes CCL5-mediated disruption of tight junctions in enterocytes. Increased intestinal permeability leads to translocation of microbial products to the liver and causes inflammation by activating TLRs.
Figure 2. Effects of the Intestinal Microbiota on Alcoholic Liver Disease

Suppressed secretion of antimicrobial peptides and proteins (AMP), and possibly EtOH itself, contribute to bacterial overgrowth and dysbiosis. Qualitative changes in the microbiota are characterized by decreased Lactobacilli in experimental models of alcohol-induced liver disease. An altered intestinal microbiota is able to produce ethanol and metabolize it into acetaldehyde. Luminal or systemic ethanol and acetaldehyde disrupt tight junctions and increase intestinal permeability. An influx of microbial products into the liver via the portal vein results in hepatic inflammation, which synergizes with ethanol to induce alcoholic liver disease. EtOH and/or acetaldehyde-induced inflammation in the intestinal lamina propria might contribute to dysfunctional tight junctions and reduced production of antimicrobial peptides and proteins by enterocytes.

Gastroenterology. Author manuscript; available in PMC 2015 May 01.
## Table 1

Changes in the intestinal microbiota associated with NAFLD and NASH in humans

<table>
<thead>
<tr>
<th>Disease</th>
<th>Comparison</th>
<th>Implicated Microbiota</th>
<th>Phylum</th>
<th>Class</th>
<th>Order</th>
<th>Family</th>
<th>Genus</th>
<th>Methodology</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy (n=30) NAFLD (n=30)</td>
<td>Healthy vs NAFLD</td>
<td>Firmicutes</td>
<td>Bacilli</td>
<td>Lactobacillales</td>
<td>Lactobacillaceae</td>
<td>↑</td>
<td>Lactobacillus</td>
<td>16S rRNA gene Pyrosequencing Stool sample</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clostridia</td>
<td>Clostridiales</td>
<td>Lachnospiraceae</td>
<td>Ruminococcaceae</td>
<td>↓</td>
<td>Oscillospiraceae</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children: Healthy (n=16) Obese (n=25) NASH (n=22)</td>
<td>Healthy vs Obese</td>
<td>Bacteroidetes</td>
<td>↑</td>
<td>Prevotellaceae</td>
<td>Prevotella</td>
<td>↑</td>
<td>Rikenellaceae</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>↓</td>
<td>Lachnospiraceae</td>
<td>Blautia</td>
<td>↓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eubacteriaceae</td>
<td>Eubacterium</td>
<td>↓</td>
<td>Ruminococcaceae</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Healthy vs NASH</td>
<td>Bacteroidetes</td>
<td>↑</td>
<td>Prevotellaceae</td>
<td>Prevotella</td>
<td>↑</td>
<td>Rikenellaceae</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>↓</td>
<td>Lachnospiraceae</td>
<td>Blautia</td>
<td>↓</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eubacteriaceae</td>
<td>Eubacterium</td>
<td>↓</td>
<td>Ruminococcaceae</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Obese vs NASH</td>
<td>Proteobacteria</td>
<td>↑</td>
<td>Gammaproteobacteria</td>
<td>Enterobacteriaceae</td>
<td>↑</td>
<td>E. coli</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Enterobacteriaceae</td>
<td>E. coli</td>
<td>ns</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy (n=17) Steatosis (n=11) NASH (n=22)</td>
<td>Healthy vs NASH</td>
<td>Bacteroidetes</td>
<td>↓</td>
<td>Proteobacteria</td>
<td>Enterobacteriaceae</td>
<td>E. coli</td>
<td>Quantitative realtime PCR Stool sample</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Steatosis vs NASH</td>
<td>Bacteroidetes</td>
<td>↓</td>
<td>Proteobacteria</td>
<td>Enterobacteriaceae</td>
<td>E. coli</td>
<td>ns</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Comparison condition A vs condition B: ↑ Increase in condition B relative to condition A, ↓ Decrease in condition B relative to condition A, ns not significant

2 Taxonomy was updated using the NCBI Taxonomy Browser
References focus on microbiota changes associated with liver disease rather than obesity or the metabolic syndrome.
# Table 2

Changes in the intestinal microbiota associated with liver cirrhosis in humans

<table>
<thead>
<tr>
<th>Disease</th>
<th>Comparison</th>
<th>Implicated Microbiota</th>
<th>Methodology</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy (n=32) HBV cirrhotics (n=31)</td>
<td>Healthy vs HBV cirrhotics</td>
<td>Bacteroidetes ↓ Prevotella ↓ Enterococcus faecalis ↑  Faecalibacterium prauznitzii ↓ Clostridium clusters XI ↓ Clostridium clusters XIV ↓ Lactic acid bacteria ↓ (including Lactobacillus, Pediococcus, Leuconostoc, and Weissella)</td>
<td>Quantitative realtime PCR  Stool sample</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Actinobacteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proteobacteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy (n=15) HBV cirrhotics (n=16)</td>
<td>Healthy vs HBV cirrhotics</td>
<td>Actinobacteria ↓ Bifidobacterium ↓</td>
<td>Quantitative realtime PCR  Stool sample</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy (n=38) HBV cirrhotics (n=61)</td>
<td>Healthy vs HBV cirrhotics</td>
<td>Firmicutes ↑ Lactobacillus acidophilus ↑  Lactobacillus rhamnosus ↓  Lactobacillus reuteri ↓  Lactobacillus gasseri ↑</td>
<td>Quantitative realtime PCR  Stool sample</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Actinobacteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proteobacteria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy (n=24) HBV cirrhotics (n=24)  Alcoholic cirrhotics (n=12)</td>
<td>Healthy vs Cirrhotics</td>
<td>Bacteroidetes ↓ Bacteroidia ↓ Bacteroidaceae ↓ Enterococcus faecalis ↑</td>
<td>16S rRNA gene Pyrosequencing, Quantitative realtime PCR  Stool sample</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bacilli ↑ Streptococcaceae ↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clostridia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lachnospiraceae ↓  Negativicutes Veillonellaceae ↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clostridium clusters XI ↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proteobacteria ↑ Gamma-proteobacteria ↑ Enterobacteriaceae ↑  Pasteurellaceae ↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes ↑ Fusobacteria ↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Clostridium clusters XI ↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy vs Alcoholic cirrhotics</td>
<td>Bacteroidetes</td>
<td>Prevotellaceae ↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBV cirrhosis vs Alcoholic cirrhotics</td>
<td>Bacteroidetes</td>
<td>Prevotellaceae ↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease</td>
<td>Comparison¹</td>
<td>Implicated Microbiota²</td>
<td>Methodology</td>
<td>Ref.</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------</td>
<td>------------------------</td>
<td>----------------------</td>
<td>-----</td>
</tr>
<tr>
<td>Healthy (n=10)</td>
<td>Healthy vs Cirrhotics</td>
<td>Firmicutes</td>
<td>Lachnospiraceae ↓, Ruminococcaceae ↓, Clostridium Incertae sedis XIV ↓, Leuconostocaceae ↑, Lactobacillaceae ↑</td>
<td>16S rRNA gene Pyrosequencing Stool sample</td>
</tr>
<tr>
<td>Cirrhotics (n=25)</td>
<td></td>
<td>Class</td>
<td>Order</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Ruminococcaceae ↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Clostridium Incertae sedis XIV ↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Leuconostocaceae ↑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Lactobacillaceae ↑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fusobacteria</td>
<td>Enteroctoexistace ↑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fusobacteria</td>
<td>Alcaligenaceae ↑</td>
<td></td>
</tr>
<tr>
<td>Healthy (n=17)</td>
<td>Healthy vs Cirrhotics</td>
<td>Firmicutes</td>
<td>Clostridiaceae ↑</td>
<td>16S rRNA gene Pyrosequencing Stool sample</td>
</tr>
<tr>
<td>Cirrhotics (n=36)</td>
<td></td>
<td>Class</td>
<td>Order</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Lachnospiraceae ↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Ruminococcaceae ↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Acidaminococcaceae ↑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Enterococcaceae ↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proteobacteria</td>
<td>Burkholderiaceae ↑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proteobacteria</td>
<td>Enterobacteriaceae ↑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proteobacteria</td>
<td>Enterococcus ↑</td>
<td></td>
</tr>
<tr>
<td>Mucosal samples Cirrhotics vs Stool samples Cirrhotics</td>
<td>Firmicutes</td>
<td>Veillonellaceae ↑</td>
<td>Veillonella ↑</td>
<td>16S rRNA gene Pyrosequencing Stool sample, Rectosigmoid mucosal biopsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Class</td>
<td>Order</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Lachnospiraceae ↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Leuconostocaceae ↑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Roseburia ↑, Blautia ↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Firmicutes</td>
<td>Leuconostocaceae ↑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Actinobacteria</td>
<td>Propionibacteriaceae ↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Actinobacteria</td>
<td>Acidaminococcaceae ↑</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proteobacteria</td>
<td>Streptomycetaceae ↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proteobacteria</td>
<td>Vibrionaceae ↓</td>
<td></td>
</tr>
</tbody>
</table>

¹ Comparison condition A vs condition B: ↑ Increase in condition B relative to condition A, ↓ Decrease in condition B relative to condition A, ns not significant
² Taxonomy was updated using the NCBI Taxonomy Browser
³ Mixed etiology

HBV, Hepatitis B virus